BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer

Sung Kim, David Rimm, Darryl Carter, Atif Khan, Nicole Parisot, Mayra Alvarez Franco, Allen Bale, Bruce G. Haffty

Research output: Contribution to journalArticle

Abstract

Conservatively treated premenopausal breast cancer has a higher rate of local relapse as well as an increased genetic predisposition to cancer. The current study's purpose was to evaluate the interactions between BRCA-1/2 status and molecular biologic markers in a cohort of conservatively managed breast cancer patients. Seventy-six premenopausal women treated with breast-conserving surgery and radiation therapy were this study's focus. All patients were treated with wide local excision with or without axillary dissection, followed by radiation to the intact breast. Systemic therapy was administered as clinically indicated. All patients in this study had an available paraffin block from the primary tumor and agreed to undergo complete sequencing of the BRCA-1 and BRCA-2genes. The primary breast tumor tissue from each patient was immunohistochemically stained for estrogen receptor (ER), progesterone receptor (PR), p53, HER-2/neu, and Proliferating Cell Nuclear Antigen (PCNA). Of the 76 patients tested for BRCA, 50 patients had wild-type BRCA-1 and BRCA-2, 15 had variants of unclear significance, 6 had deleterious mutations in BRCA-1, and 5 had deleterious mutations in BRCA-2. p53 positivity correlated with deleterious mutations in BRCA-1 (p = 0.023), but not in BRCA-2. Though not significant, there was a trend for ER and PR negativity to correlate with BRCA-1 mutation (p = 0.087 and 0.054, respectively); there were no correlations between ER, PR, and BRCA-2. Though not significant, all 11 tumors with BRCA mutations were HER-2/neu negative. Patients with BRCA mutations have a unique molecular profile. These data can be helpful in understanding differences in the biologic behavior of patients with familial breast cancers.

Original languageEnglish (US)
Pages (from-to)167-174
Number of pages8
JournalBreast Journal
Volume9
Issue number3
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Biomarkers
Breast Neoplasms
Mutation
Progesterone Receptors
Estrogen Receptors
Neoplasms
Segmental Mastectomy
Proliferating Cell Nuclear Antigen
Genetic Predisposition to Disease
Paraffin
Dissection
Breast
Radiotherapy
Radiation
Recurrence

Keywords

  • BRCA1
  • BRCA2
  • Breast cancer
  • Molecular markers

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Kim, S., Rimm, D., Carter, D., Khan, A., Parisot, N., Franco, M. A., ... Haffty, B. G. (2003). BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. Breast Journal, 9(3), 167-174. https://doi.org/10.1046/j.1524-4741.2003.09307.x

BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. / Kim, Sung; Rimm, David; Carter, Darryl; Khan, Atif; Parisot, Nicole; Franco, Mayra Alvarez; Bale, Allen; Haffty, Bruce G.

In: Breast Journal, Vol. 9, No. 3, 05.2003, p. 167-174.

Research output: Contribution to journalArticle

Kim, S, Rimm, D, Carter, D, Khan, A, Parisot, N, Franco, MA, Bale, A & Haffty, BG 2003, 'BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer', Breast Journal, vol. 9, no. 3, pp. 167-174. https://doi.org/10.1046/j.1524-4741.2003.09307.x
Kim, Sung ; Rimm, David ; Carter, Darryl ; Khan, Atif ; Parisot, Nicole ; Franco, Mayra Alvarez ; Bale, Allen ; Haffty, Bruce G. / BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer. In: Breast Journal. 2003 ; Vol. 9, No. 3. pp. 167-174.
@article{5db0d256dcb84c40bf63dbf502fca50c,
title = "BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer",
abstract = "Conservatively treated premenopausal breast cancer has a higher rate of local relapse as well as an increased genetic predisposition to cancer. The current study's purpose was to evaluate the interactions between BRCA-1/2 status and molecular biologic markers in a cohort of conservatively managed breast cancer patients. Seventy-six premenopausal women treated with breast-conserving surgery and radiation therapy were this study's focus. All patients were treated with wide local excision with or without axillary dissection, followed by radiation to the intact breast. Systemic therapy was administered as clinically indicated. All patients in this study had an available paraffin block from the primary tumor and agreed to undergo complete sequencing of the BRCA-1 and BRCA-2genes. The primary breast tumor tissue from each patient was immunohistochemically stained for estrogen receptor (ER), progesterone receptor (PR), p53, HER-2/neu, and Proliferating Cell Nuclear Antigen (PCNA). Of the 76 patients tested for BRCA, 50 patients had wild-type BRCA-1 and BRCA-2, 15 had variants of unclear significance, 6 had deleterious mutations in BRCA-1, and 5 had deleterious mutations in BRCA-2. p53 positivity correlated with deleterious mutations in BRCA-1 (p = 0.023), but not in BRCA-2. Though not significant, there was a trend for ER and PR negativity to correlate with BRCA-1 mutation (p = 0.087 and 0.054, respectively); there were no correlations between ER, PR, and BRCA-2. Though not significant, all 11 tumors with BRCA mutations were HER-2/neu negative. Patients with BRCA mutations have a unique molecular profile. These data can be helpful in understanding differences in the biologic behavior of patients with familial breast cancers.",
keywords = "BRCA1, BRCA2, Breast cancer, Molecular markers",
author = "Sung Kim and David Rimm and Darryl Carter and Atif Khan and Nicole Parisot and Franco, {Mayra Alvarez} and Allen Bale and Haffty, {Bruce G.}",
year = "2003",
month = "5",
doi = "10.1046/j.1524-4741.2003.09307.x",
language = "English (US)",
volume = "9",
pages = "167--174",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - BRCA status, molecular markers, and clinical variables in early, conservatively managed breast cancer

AU - Kim, Sung

AU - Rimm, David

AU - Carter, Darryl

AU - Khan, Atif

AU - Parisot, Nicole

AU - Franco, Mayra Alvarez

AU - Bale, Allen

AU - Haffty, Bruce G.

PY - 2003/5

Y1 - 2003/5

N2 - Conservatively treated premenopausal breast cancer has a higher rate of local relapse as well as an increased genetic predisposition to cancer. The current study's purpose was to evaluate the interactions between BRCA-1/2 status and molecular biologic markers in a cohort of conservatively managed breast cancer patients. Seventy-six premenopausal women treated with breast-conserving surgery and radiation therapy were this study's focus. All patients were treated with wide local excision with or without axillary dissection, followed by radiation to the intact breast. Systemic therapy was administered as clinically indicated. All patients in this study had an available paraffin block from the primary tumor and agreed to undergo complete sequencing of the BRCA-1 and BRCA-2genes. The primary breast tumor tissue from each patient was immunohistochemically stained for estrogen receptor (ER), progesterone receptor (PR), p53, HER-2/neu, and Proliferating Cell Nuclear Antigen (PCNA). Of the 76 patients tested for BRCA, 50 patients had wild-type BRCA-1 and BRCA-2, 15 had variants of unclear significance, 6 had deleterious mutations in BRCA-1, and 5 had deleterious mutations in BRCA-2. p53 positivity correlated with deleterious mutations in BRCA-1 (p = 0.023), but not in BRCA-2. Though not significant, there was a trend for ER and PR negativity to correlate with BRCA-1 mutation (p = 0.087 and 0.054, respectively); there were no correlations between ER, PR, and BRCA-2. Though not significant, all 11 tumors with BRCA mutations were HER-2/neu negative. Patients with BRCA mutations have a unique molecular profile. These data can be helpful in understanding differences in the biologic behavior of patients with familial breast cancers.

AB - Conservatively treated premenopausal breast cancer has a higher rate of local relapse as well as an increased genetic predisposition to cancer. The current study's purpose was to evaluate the interactions between BRCA-1/2 status and molecular biologic markers in a cohort of conservatively managed breast cancer patients. Seventy-six premenopausal women treated with breast-conserving surgery and radiation therapy were this study's focus. All patients were treated with wide local excision with or without axillary dissection, followed by radiation to the intact breast. Systemic therapy was administered as clinically indicated. All patients in this study had an available paraffin block from the primary tumor and agreed to undergo complete sequencing of the BRCA-1 and BRCA-2genes. The primary breast tumor tissue from each patient was immunohistochemically stained for estrogen receptor (ER), progesterone receptor (PR), p53, HER-2/neu, and Proliferating Cell Nuclear Antigen (PCNA). Of the 76 patients tested for BRCA, 50 patients had wild-type BRCA-1 and BRCA-2, 15 had variants of unclear significance, 6 had deleterious mutations in BRCA-1, and 5 had deleterious mutations in BRCA-2. p53 positivity correlated with deleterious mutations in BRCA-1 (p = 0.023), but not in BRCA-2. Though not significant, there was a trend for ER and PR negativity to correlate with BRCA-1 mutation (p = 0.087 and 0.054, respectively); there were no correlations between ER, PR, and BRCA-2. Though not significant, all 11 tumors with BRCA mutations were HER-2/neu negative. Patients with BRCA mutations have a unique molecular profile. These data can be helpful in understanding differences in the biologic behavior of patients with familial breast cancers.

KW - BRCA1

KW - BRCA2

KW - Breast cancer

KW - Molecular markers

UR - http://www.scopus.com/inward/record.url?scp=0037736549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037736549&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4741.2003.09307.x

DO - 10.1046/j.1524-4741.2003.09307.x

M3 - Article

C2 - 12752624

AN - SCOPUS:0037736549

VL - 9

SP - 167

EP - 174

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 3

ER -